ChengDa Pharmaceuticals Co. Ltd. (SHE:301201) — Market Cap & Net Worth
Market Cap & Net Worth: ChengDa Pharmaceuticals Co. Ltd. (301201)
ChengDa Pharmaceuticals Co. Ltd. (SHE:301201) has a market capitalization of $776.99 Million (CN¥5.31 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #10114 globally and #2682 in its home market, demonstrating a 0.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ChengDa Pharmaceuticals Co. Ltd.'s stock price CN¥34.32 by its total outstanding shares 154713824 (154.71 Million). Also see 301201 total assets for a full breakdown of the balance sheet.
ChengDa Pharmaceuticals Co. Ltd. Market Cap History: 2022 to 2026
ChengDa Pharmaceuticals Co. Ltd.'s market capitalization history from 2022 to 2026. Data shows change from $702.65 Million to $776.99 Million (-16.15% CAGR). Also see how efficiently does ChengDa Pharmaceuticals Co. Ltd. generate cash for how efficiently the company converts equity into cash flow.
ChengDa Pharmaceuticals Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ChengDa Pharmaceuticals Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 301201 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.27x
ChengDa Pharmaceuticals Co. Ltd.'s market cap is 2.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $702.65 Million | $411.46 Million | $106.48 Million | 1.71x | 6.60x |
| 2023 | $569.33 Million | $414.30 Million | $90.98 Million | 1.37x | 6.26x |
| 2024 | $456.87 Million | $333.13 Million | -$28.10 Million | 1.37x | N/A |
| 2025 | $921.43 Million | $406.37 Million | -$11.93 Million | 2.27x | N/A |
Competitor Companies of 301201 by Market Capitalization
Companies near ChengDa Pharmaceuticals Co. Ltd. in the global market cap rankings as of September 19, 2026. Review 301201 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ChengDa Pharmaceuticals Co. Ltd. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
ChengDa Pharmaceuticals Co. Ltd. Historical Marketcap From 2022 to 2026
Between 2022 and today, ChengDa Pharmaceuticals Co. Ltd.'s market cap moved from $702.65 Million to $ 776.99 Million, with a yearly change of -16.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥776.99 Million | -15.68% |
| 2025 | CN¥921.43 Million | +101.68% |
| 2024 | CN¥456.87 Million | -19.75% |
| 2023 | CN¥569.33 Million | -18.97% |
| 2022 | CN¥702.65 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of ChengDa Pharmaceuticals Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $776.99 Million USD |
| MoneyControl | $776.99 Million USD |
| MarketWatch | $776.99 Million USD |
| marketcap.company | $776.99 Million USD |
| Reuters | $776.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and A… Read more